Search Results: keywords:"biosimilar biological products"

  • S. 5459 — To amend title XI of the Social Security Act to alter when biosimilar biological products are eligible for price negotiations under the Medicare program.
    Status:Introduced in Senate
    Words:2,447

    The bill, known as the “Biosimilars Access and Affordability Act,” proposes changes to the Social Security Act regarding when biosimilar biological products can be subject to price negotiations under the Medicare program. It modifies specific sections to allow for extensions and delays in...

    Simple Explanation

    The bill suggests changing some rules about how and when the government can talk with companies about the prices of certain medicines that are like copies of existing ones, known as biosimilars, to make sure they don't cost too much. It also adds rules that could charge companies money if they don't sell these copy-medicines when they said they would start.

  • S. 3934 — To require the Secretary of Health and Human Services to establish a demonstration project to increase access to biosimilar biological products under the Medicare program.
    Status:Introduced in Senate
    Words:1,271

    S. 3934 proposes the creation of a three-year nationwide project led by the Secretary of Health and Human Services to boost access to biosimilar biological products under Medicare. This demonstration project would evaluate the benefits of a shared savings payment plan for...

    Simple Explanation

    S. 3934 is a plan to try using special versions of medicines called biosimilars in Medicare, where doctors can earn extra money if they choose these medicines, but it won't cost patients more. The project will happen over three years, and it will help decide if using these medicines can keep costs the same while making sure people get good care.